Xarelto, a blood thinner prescribed to patients who are at risk of stroke due to blood clots, has been linked to internal bleeding, which could be fatal.
Xarelto is a drug manufactured by Bayer and is marketed by Johnson and Johnson – both of which are giant healthcare companies, and have made the drug among the bestsellers in the market. Xarelto is a preferred prescription by many doctors as it does not require blood test before the patient is given a prescription unlike other blood thinning drugs.
Xarelto claims to be “the number one prescribed novel oral anticoagulant in the US”. It is approved by the Food and Drug Administration to reduce risk of blood clots in legs and lungs of patients who had knee or hip replacement surgery. It was also approved to reduce risk of both thrombotic and hemorrhagic strokes and to treat Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
But frightening side effects, including internal bleeding, were cited in patients who are taking Xarelto. There is no immediate antidote for internal bleeding once it has already begun. Other damaging side effects of Xarelto include white blood cell deficiency, hemorrhage and life-threatening allergic reactions.
These side effects are the reason why both J & J and Bayer are under scrutiny. In previous Xarelto lawsuits, plaintiffs claimed that Bayer and Johnson and Johnson should be held accountable for the financial recovery of Xarelto’s victims. These include funeral expenses, medical expenses, pain and suffering as well as medical expenses.